Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
524 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06256588 | A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma(JADE) | recruiting | Phase 3 | 864 | GlaxoSmithKlineINDUSTRY | 31 | May 26, 2026 | clinicaltrials |
| NCT06551142 | A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)(PanTumor-101) | recruiting | Phase 1 | 845 | GlaxoSmithKlineINDUSTRY | 13 | May 22, 2026 |
| clinicaltrials |
| NCT06567782 | A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer(AZUR-4) | recruiting | Phase 2 | 120 | GlaxoSmithKlineINDUSTRY | 6 | May 22, 2026 | clinicaltrials |
| NCT04126200 | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)(DREAMM 5) | active not recruiting | Phase 1 / Phase 2 | 208 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT07084896 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 106 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT05064358 | Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma(DREAMM 14) | completed | Phase 2 | 177 | GlaxoSmithKlineINDUSTRY | 18 | May 5, 2026 | clinicaltrials |
| NCT06077877 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 42 | GlaxoSmithKlineINDUSTRY | 3 | Apr 24, 2026 | clinicaltrials |
| NCT04246047 | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma(DREAMM 7) | active not recruiting | Phase 3 | 494 | GlaxoSmithKlineINDUSTRY | 13 | Apr 23, 2026 | clinicaltrials |
| NCT06868654 | China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma(DREAMM 7) | active not recruiting | Phase 3 | 72 | GlaxoSmithKlineINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06868667 | Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma(DREAMM 7) | active not recruiting | Phase 3 | 24 | GlaxoSmithKlineINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06710847 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors(SYLVER) | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 7 | Feb 2, 2026 | clinicaltrials |
| NCT05855200 | Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | recruiting | Phase 3 | 892 | GlaxoSmithKlineINDUSTRY | 28 | Jan 23, 2026 | clinicaltrials |
| NCT04544995 | Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP) | terminated | Phase 1 | 47 | GlaxoSmithKlineINDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07108270 | A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC) | recruiting | Phase 2 | 30 | GlaxoSmithKlineINDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT04398680 | A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function(DREAMM 13) | withdrawn | Phase 1 | 0 | GlaxoSmithKlineINDUSTRY | 3 | Dec 4, 2025 | clinicaltrials |
| NCT04091126 | Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma(DREAMM 9) | active not recruiting | Phase 1 | 118 | GlaxoSmithKlineINDUSTRY | 10 | Nov 28, 2025 | clinicaltrials |
| NCT06640049 | A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China(China AZUR-1) | active not recruiting | Phase 2 | 23 | GlaxoSmithKlineINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT04446351 | Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 107 | GlaxoSmithKlineINDUSTRY | 4 | Oct 27, 2025 | clinicaltrials |
| NCT03525678 | A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody | completed | Phase 2 | 221 | GlaxoSmithKlineINDUSTRY | 8 | Sep 3, 2025 | clinicaltrials |
| NCT03828292 | An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments | completed | Phase 1 | 15 | GlaxoSmithKlineINDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT04581824 | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 243 | GlaxoSmithKlineINDUSTRY | 12 | Aug 8, 2025 | clinicaltrials |
| NCT06317311 | A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer(RUBY-J) | active not recruiting | Phase 2 | 41 | GlaxoSmithKlineINDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04915755 | Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease(ZEST) | active not recruiting | Phase 3 | 40 | GlaxoSmithKlineINDUSTRY | 27 | Jul 16, 2025 | clinicaltrials |
| NCT06897527 | A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC) | not yet recruiting | Phase 4 | 100 | GlaxoSmithKlineINDUSTRY | 0 | Jul 8, 2025 | clinicaltrials |
| NCT06926673 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3 | completed | Phase 2 | 62 | GlaxoSmithKlineINDUSTRY | 6 | Jul 3, 2025 | clinicaltrials |
| NCT03739710 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 175 | GlaxoSmithKlineINDUSTRY | 12 | Jun 15, 2025 | clinicaltrials |
| NCT06790303 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2 | terminated | Phase 2 | 8 | GlaxoSmithKlineINDUSTRY | 3 | Jun 4, 2025 | clinicaltrials |
| NCT06887933 | A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer | not yet recruiting | Phase 4 | 67 | GlaxoSmithKlineINDUSTRY | 0 | Mar 21, 2025 | clinicaltrials |
| NCT02783300 | An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma(Meteor 1) | completed | Phase 1 | 297 | GlaxoSmithKlineINDUSTRY | 4 | Mar 10, 2025 | clinicaltrials |
| NCT06655818 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM | terminated | Phase 1 / Phase 2 | 4 | GlaxoSmithKlineINDUSTRY | 2 | Mar 3, 2025 | clinicaltrials |
| NCT05496231 | A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age | completed | Phase 1 / Phase 2 | 1,080 | GlaxoSmithKlineINDUSTRY | 8 | Feb 3, 2025 | clinicaltrials |
| NCT02723955 | Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1) | completed | Phase 1 | 829 | GlaxoSmithKlineINDUSTRY | 9 | Dec 27, 2024 | clinicaltrials |
| NCT03763370 | Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma | available | — | — | GlaxoSmithKlineINDUSTRY | 0 | Oct 15, 2024 | clinicaltrials |
| NCT04428333 | Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(INDUCE-4) | terminated | Phase 3 | 117 | GlaxoSmithKlineINDUSTRY | 19 | Oct 9, 2024 | clinicaltrials |
| NCT03447314 | Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors | completed | Phase 1 | 54 | GlaxoSmithKlineINDUSTRY | 4 | Sep 23, 2024 | clinicaltrials |
| NCT03693612 | GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 26 | GlaxoSmithKlineINDUSTRY | 3 | Aug 28, 2024 | clinicaltrials |
| NCT04128696 | Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(INDUCE-3) | terminated | Phase 3 | 315 | GlaxoSmithKlineINDUSTRY | 26 | Jul 10, 2024 | clinicaltrials |
| NCT04772053 | Molecular Disease Characterization Initiative (MDCI) | terminated | Phase 2 | 6 | GlaxoSmithKlineINDUSTRY | 2 | Apr 19, 2024 | clinicaltrials |
| NCT04349280 | A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer | terminated | Phase 1 | 25 | GlaxoSmithKlineINDUSTRY | 5 | Apr 18, 2024 | clinicaltrials |
| NCT03848845 | Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)(DREAMM 4) | completed | Phase 1 / Phase 2 | 41 | GlaxoSmithKlineINDUSTRY | 4 | Apr 9, 2024 | clinicaltrials |
| NCT03629886 | Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study | completed | Phase 4 | 6,051 | GlaxoSmithKlineINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06160609 | Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM | terminated | Phase 1 / Phase 2 | 9 | GlaxoSmithKlineINDUSTRY | 3 | Mar 12, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials